Please ensure Javascript is enabled for purposes of website accessibility

3 Great Stocks for Your IRA

By Keith Speights - Updated Feb 6, 2018 at 4:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These dividend stars could brighten your retirement portfolio.

Individual retirement accounts (IRAs) are, without question, one of the best vehicles available to investors to grow their retirement portfolios. And they're an ideal place to hold stocks that pay high dividends. Why? You have to pay taxes on any dividends received in a normal trading account, but taxes are deferred in a traditional IRA. 

But which stocks to choose? I like AT&T (T 1.84%), Iron Mountain (IRM 3.15%), and Pfizer (PFE 3.00%). Here's why these are three great stocks to include in your IRA.

Golden egg with IRA written on it on top of cash

Image source: Getty Images.


AT&T isn't just a run-of-the-mill dividend stock, it's one of an elite group known as Dividend Aristocrats. The telecom giant has increased its dividend for 34 consecutive years. AT&T's dividend yield currently stands at 5.11%.

Its yield certainly makes AT&T attractive to income investors. But is that all AT&T has to offer? You might think so at first glance, considering the stock's performance has lagged well behind the S&P 500 index over the past five years. However, Wall Street analysts think the telecom company will grow earnings at a much greater rate in the future than it has in the recent past. I think they're probably right.

One reason for optimism about AT&T is the company's investment in building out its high-speed 5G wireless network. Right now, AT&T appears to be the leader in this effort, which could position it well to benefit with the rise of self-driving cars and augmented-reality applications.

The other reason for optimism is AT&T's pending acquisition of Time Warner. Although there have been concerns that the deal won't pass regulatory hurdles, AT&T CEO Randall Stephenson recently expressed confidence that the merger will be completed. Buying Time Warner would give the company a lot of content to compete more effectively with its DIRECTV business.     

Iron Mountain

I view Iron Mountain as the kind of stock you can buy and hold forever -- or pretty close to it. One factor that makes the provider of records storage and information management so appeal its its dividend, which yields nearly 6.8%. 

The really good news is that Iron Mountain's dividend not only appears to be safe, but it should also grow in the future. Iron Mountain has grown its dividend by nearly 24% since early 2015 and anticipates raising its dividend by at least 4% annually over the next few years.

Iron Mountain doesn't have a monopoly in the records storage business, but the company isn't too far away from claiming one. Its customer base includes 230,000 organizations around the world. Around 95% of the Fortune 1000 companies use Iron Mountain's services.

There's even more good news for investors: Organizations continue to generate more and more records and data that they need to store, and that creates significant growth opportunities for Iron Mountain. 


Pfizer has ranked among the best healthcare dividend stocks on the market for quite a while. And it's still one of the best, with a dividend yield of 3.7%.

Like AT&T, though, Pfizer's stock performance hasn't been as good as the S&P 500 index in recent years. I believe better days are ahead for the big drugmaker, however. Market research firm EvaluatePharma included two of Pfizer's products on its list of the top five highest-growth drugs of 2018. Coming in at No. 5 on the list was cancer drug Ibrance. Anticoagulant Eliquis, which is marketed by Pfizer and partner Bristol-Myers Squibb, placed fourth on EvaluatePharma's ranking.

There's also Pfizer's deep pipeline to consider. The company thinks it could win approval for up to 15 potential blockbusters over the next five years. To put that into perspective, Pfizer launched only seven blockbuster drugs in the past 10 years. 

Pfizer was quiet on the business development front in 2017. I expect the company will make an acquisition or two this year, which could drive even more growth.

Think long term

One great thing about IRAs is that they encourage Americans to think about their long-term future. Thinking long-term is key for being successful in investing.

Any or all of these stocks could encounter headwinds this year. However, I expect AT&T, Iron Mountain, and Pfizer to generate solid gains over the long run. All three companies have solid business models and create strong cash flows that they use to reward shareholders and reinvest into their businesses. That's exactly what you want when investing your money intended for retirement. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AT&T Inc. Stock Quote
AT&T Inc.
$20.99 (1.84%) $0.38
Pfizer Inc. Stock Quote
Pfizer Inc.
$51.59 (3.00%) $1.50
Iron Mountain Incorporated Stock Quote
Iron Mountain Incorporated
$49.46 (3.15%) $1.51
Time Warner Inc. Stock Quote
Time Warner Inc.
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$78.96 (1.64%) $1.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.